Filing Details
Cocrystal Pharma, Inc. (NASDAQ:COCP) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:COCP
Cocrystal Pharma, Inc. (COCP) Files Quarterly Report for Q0
Cocrystal Pharma, Inc. (NASDAQ:COCP) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
At publication ·
What changed
Cocrystal Pharma, Inc. (NASDAQ:COCP) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Cocrystal Pharma, Inc. (NASDAQ: COCP) filed its quarterly report (Form 10-Q) on August 13, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $1.10 with a market capitalization of $11.0 million as of the filing date.
- The quarterly report contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing, though with less detail than the annual 10-K report.
Market Context
Cocrystal Pharma, Inc.'s stock currently trades at $1.10 with a market capitalization of $11.0M.
The 10-Q provides Cocrystal Pharma, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Cocrystal Pharma, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View COCP Stock Page
Frequently Asked Questions
Where can I read COCP's SEC filings?
Browse all filings on our COCP SEC filings page.
What types of SEC filings does Cocrystal Pharma, Inc. file?
Public companies like Cocrystal Pharma, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.